Bonnie Fletcher Price

Bonnie’s practice focuses on life sciences patent litigation, including Hatch-Waxman litigation related to abbreviated new drug applications (ANDAs) and biologics litigation under the Biologics Price Competition and Innovation Act (BPCIA). Bonnie’s litigation experience includes all aspects of pre-trial and trial district court practice, inter partes review before the Patent Trial and Appeal Board, and arbitration.

Bonnie’s pro bono practice includes representing veterans before the US Court of Appeals for Veterans Claims asylum seekers in immigration proceedings and appeals before the Board of Immigration Appeals.

Prior to launching her legal career, Bonnie received her PhD in neuroscience and conducted research at the National Institute on Aging. Her research explored the cellular and molecular mechanisms underlying cognitive aging, focusing on epigenetic contributions to altered mRNA and protein expression. She has experience employing numerous techniques and methodologies, including animal models of learning and memory, in vivo electrophysiology, pharmacological interventions, stereological quantification, confocal microscopy, quantitative immunohistochemistry, in situ mRNA detection and quantification, and quantitative western blotting.

Bonnie’s recent representative experience

• Biofer S.p.A. v. Vifor (International) AG: Representing Vifor in patent infringement litigation concerning the iron replacement product Injectafer.
• Scilex Pharmaceuticals, Inc. et al. v. Aveva Drug Delivery Systems, Inc. et al.: Representing Scilex and co-plaintiffs in Hatch-Waxman litigation concerning their ZTlido product for the treatment of pain associated with post-herpetic neuralgia against ANDA filers Aveva and Apotex.
• Newron Pharmaceuticals SpA et al. v. Aurobindo Pharma Limited et al.: Representing Newron and co-plaintiffs in Hatch-Waxman litigation concerning Xadago (safinamide), an adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.
• Samsung Bioepis Co., Ltd. v. Alexion Pharmaceuticals, Inc.: Representing Samsung Bioepis in inter partes review of patents concerning the treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement.
• Sight Sciences, Inc. v. Ivantis, Inc.: Representing Sight Sciences in patent infringement litigation concerning the Hydrus Microstent implant for reduction of intraocular pressure in patients with mild to moderate primary open-angle glaucoma.
• NeuroDerm Ltd. v. AbbVie Inc.: Representing NeuroDerm in inter partes review of patent concerning levodopa/carbidopa formulations for continuous subcutaneous administration.
• RSB Spine, LLC v. DePuy Synthes Sales, Inc. et al.: Representing RSB Spine in patent infringement litigation concerning various low-profile interbody plate spacer devices for spinal fusion.
• RSB Spine, LLC v. Precision Spine, Inc.: Represented RSB Spine in patent infringement litigation concerning various low-profile interbody plate spacer devices for spinal fusion.
• Journey Medical Corporation et al. v. Perrigo Pharma International DAC: Represented Journey Medical in Hatch-Waxman litigation concerning its Zilxi product for the treatment of rosacea, its Amzeeq product for the treatment of acne, and its Qbrexza product for the treatment of primary axillary hyperhidrosis against ANDA filer Perrigo.
• Journey Medical Corporation et al. v. Teva Pharmaceuticals, Inc. et al.: Represented Journey Medical in Hatch-Waxman litigation concerning its Qbrexza (glycopyrronium cloth), a product for the treatment of primary axillary hyperhidrosis, against ANDA filer Perrigo.
• BioDelivery Sciences International, Inc. et al. v. Alvogen Pb Research & Development LLC et al.*: Represented BioDelivery Sciences International in Hatch-Waxman litigation related to Belbuca (buprenorphine buccal film), a product for the management of pain, against ANDA filers Alvogen Pb and Chemo Research.
• AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. (1-18-cv-00664 (D. Del.))*: Represented AstraZeneca AB in Hatch-Waxman litigation related to Farxiga (dapagliflozin), a product for improved glycemic control in adults with type 2 diabetes mellitus, against ANDA filer Zydus.
• AbbVie Inc. v. Boehringer Ingelheim International GmbH (17-cv-01065 (D.Del.))*: Represented AbbVie in BPCIA litigation related to Humira.

* Representation handled prior to joining Cooley.

Bonnie’s speaking engagements

• Co-presenter, "Life Sciences Litigation: Hatch-Waxman, 2023 Year in Review" Cooley Rx series, January 2024
• Co-presenter of “Weathering the Storm: In Search of a Safe Harbor,” Cooley at MassBio – Life Sciences IP Seminar, September 2023
• Co-presenter of “A CREATES Act Primer,” Cooley Rx series, May 2023

Bonnie’s publications

• Myrum C, Kittleson J, De S, Fletcher BR, Castellano J, Kundu G, Becker KG, Rapp PR. “Survey of the Arc Epigenetic Landscape in Normal Cognitive Aging.” Molecular Neurobiology, 2020, 57(6):2727-40.
• Sewal A, Patzke H, Perez E, Park P, Lehrmann E, Zhang Y, Becker K, Fletcher BR, Long JM, Rapp PR. “Experience modulates the effects of histone deacetylase inhibitors on gene and protein expression in the hippocampus: impaired plasticity in aging.” Journal of Neuroscience, 2015, 35(33):11729-42.
• Fletcher BR, Hill GS, Long JM, Gallagher M, Shapiro ML, Rapp PR. “A fine balance: regulation of hippocampal Arc/Arg3.1 transcription, translation and degradation in a rat model of normal cognitive aging.” Neurobiology of Learning and Memory, 2014, 115:58-67.
• Castellano JF*, Fletcher BR*, Patzke H, Long JM, Sewal A, Kim DH, Kelley-Bell B, Rapp PR. “Reassessing the effects of histone deacetylase inhibitors on hippocampal memory and cognitive aging.” Hippocampus, 2014, 24(8):1006-16. *Co-first authors
• Fletcher BR, Rapp PR. “Normal Neurocognitive Aging,” in “Handbook of Psychology, Second Edition” (Irving B. Weiner ed., 2012). John Wiley & Sons, Ltd. 
• Castellano JF*, Fletcher BR*, Kelley-Bell B, Kim DH, Gallagher M, Rapp PR. “Age-Related Memory Impairment is Associated with Disrupted Multivariate Epigenetic Coordination in the Hippocampus.” PLoS ONE, 2012, 7(3): e33249. *Co-first authors
• Calhoun ME, Yi S, Zentko DC, Fletcher BR, Gallagher M, Rapp PR. “No reduction in spinophilin-positive dendritic spine number or spinophilin protein levels in hippocampus of cognitively-impaired aged rats.” Neurobiology of Aging, 2008, 29(8): 1256-64.
• Fletcher BR, Baxter MG, Guzowski JF, Shapiro ML, Rapp PR. “Selective cholinergic depletion of the hippocampus spares both behaviorally induced Arc transcription and spatial learning and memory.” Hippocampus, 2007, 17(3):227-34.
• Fletcher BR, Calhoun ME, Rapp PR, Shapiro ML. “Fornix lesions decouple the induction of hippocampal arc transcription from behavior but not plasticity.” Journal of Neuroscience. 2006 February 1;26(5):1507-15.
• Sciortino CM, Shrode LD, Fletcher BR, Harte PJ, Romero MF. “Localization of endogenous and recombinant Na(+)-driven anion exchanger protein NDAE1 from Drosophila melanogaster.” Am J Physiol Cell Physiol, 2001, 281(2):449-63.